All times are listed in CEST (Central European Summer Time)
Browsing Over 461 Presentations
Sort By
Adjuvant treatment luminal in breast cancer (ID 38)
Gene-expression signature for treatment decision-making: Who to test? Which signature? (ID 426)
Lecture Time
10:45 - 10:45
Session Name
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
10:45 - 12:15
Adjuvant treatment luminal in breast cancer (ID 38)
Neoadjuvant therapy: Endocrine therapy or chemotherapy? (ID 427)
Lecture Time
10:45 - 10:45
Session Name
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
10:45 - 12:15
Adjuvant treatment luminal in breast cancer (ID 38)
Endocrine therapy beyond 5 years: Who to treat and for what duration (ID 428)
Lecture Time
10:45 - 10:45
Speakers
Authors
Session Name
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
10:45 - 12:15
Adjuvant treatment luminal in breast cancer (ID 38)
Optimal management of endocrine therapy toxicity (ID 429)
Lecture Time
10:45 - 10:45
Session Name
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
10:45 - 12:15
Adjuvant treatment luminal in breast cancer (ID 38)
Q&A (ID 430)
Lecture Time
10:45 - 10:45
Speakers
Authors
Session Name
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
10:45 - 12:15
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)
Welcome and Introduction (ID 435)
Lecture Time
12:30 - 12:30
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
12:30 - 13:30
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)
Predicting Risk of Recurrence in HR-positive, HER2-negative Early Breast Cancer: A Focus on Clinicopathological Factors (ID 436)
Lecture Time
12:30 - 12:30
Speakers
Authors
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
12:30 - 13:30
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)
Tools to Guide Risk Assessment and Adjuvant Treatment Decisions in HR-positive, HER2-negative Early Breast Cancer: A Focus on Best Practices (ID 437)
Lecture Time
12:30 - 12:30
Speakers
Authors
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
12:30 - 13:30
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)
Impact of CDK4/6 Inhibitors as Adjuvant Therapy in HR-positive, HER2-negative Early Breast Cancer: A Focus on Recent Evidence (ID 438)
Lecture Time
12:30 - 12:30
Speakers
Authors
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
12:30 - 13:30
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)
Optimizing the Use of CDK4/6 Inhibitors as Adjuvant Therapy in HR-positive, HER2-negative Early Breast Cancer: A Focus on Patient Management (ID 439)
Lecture Time
12:30 - 12:30
Speakers
Authors
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
12:30 - 13:30
AiCME - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice (ID 37)
Questions and Take-Home Learnings (ID 440)
Lecture Time
12:30 - 12:30
Speakers
Authors
Room
Hamburg Hall
Date
Thu, 05.05.2022
Time
12:30 - 13:30
Antibody drug conjugates (ADCs) to treat breast cancer (ID 34)
TROP2-targeted ADCs in breast cancer (ID 390)
Lecture Time
14:45 - 14:45
Room
Munich Hall
Date
Wed, 04.05.2022
Time
14:45 - 16:15